<DOC>
	<DOCNO>NCT00606749</DOCNO>
	<brief_summary>The purpose study determine whether KC706 effective prevention heal blister patient pemphigus vulgaris , patient remain stable dos corticosteroid and/or immunosuppressant .</brief_summary>
	<brief_title>Use KC706 Treatment Pemphigus Vulgaris</brief_title>
	<detailed_description>The present study design follow-up pre-clinical observation administration KC706 associate prevention development lesion mouse model PV . Patients participate study active disease spite ongoing treatment corticosteroid and/or immunosuppressive agent . The dose chosen clinical study 300 mg daily . The primary assessment interest pemphigus lesion status dose KC706 .</detailed_description>
	<mesh_term>Pemphigus</mesh_term>
	<criteria>At least 18 year age ; Diagnosis pemphigus vulgaris Patients must take require either corticosteroid therapy immunosuppressive therapy ; Immunosuppressive therapy , , administer stable dose least 60 day prior Baseline Visit welltolerated , without expectation need increase dose next 30 day ; Corticosteroids , , administer stable dose least 30 day prior Baseline Visit without expectation need increase dose next 30 day ; Patients active PV skin , scalp mucosal lesion meet least one follow criterion Baseline Visit : &gt; 3 new lesions/week every week previous 3 week ( skin , scalp , and/or mucosal ) , heal occur rate match appearance new lesion ; At least 3 active , establish lesion Pemphigus Lesion Score least 2 ; skin scalp lesion must ≥ 5mm diameter qualify ; size requirement mucosal lesion ; , 1 large active establish skin , scalp , mucosal lesion &gt; 10 mm ; Accessibility vein suitable venipuncture ; Patients must cooperative , able read , understand give inform consent , able adhere study visit schedule protocol requirement ; , Patients must willing follow adequate contraceptive measure study ( sex ) . Any history opportunistic infection within 3 month prior receive study drug ; Infection HIV ; Past present diagnosis hepatitis confirm serology elevate hepatic enzyme ; History alcoholic liver disease cirrhosis ; Clinically significant concurrent medical disease laboratory abnormality evidence one following : Hepatobiliary AST ALT ≥ 1.5 × upper limit normal ( ULN ) ; alkaline phosphatase ≥ 1.5 × ULN ; , total bilirubin &gt; 90 % ULN ; Renal serum creatinine &gt; 1.5 mg/dL ; , significant proteinuria &gt; 2+ urinary dip test ; Hematologic hemoglobin &lt; 11 mg/dL ; leukocytes &lt; 3.5 × 109/L ; neutrophil &lt; 1.5 × 109/L ; , platelets &lt; 100 × 109/L ; Presence history malignancy ; Uncontrolled diabetes ( define diabetes require hospitalization emergency care 3 month prior first dose study drug ) ; History suspicion Gilbert 's syndrome ; Significant blood loss ( &gt; 500 mL ) within 28 day prior receipt study drug ; Use investigational drug within 30 day screen , long drug expect longacting effect ( e.g. , modulation Bcell activity ) ; Use Rituximab within past 6 month ; Use intravenous IgG within past 3 month , Current recent history ( within 12 month screen ) drug substance abuse , include alcohol ; Known suspect pregnancy ; nursing mother ; Clinically significant abnormality screen physical examination perform Baseline Visit , laboratory testing , vital sign electrocardiogram suggestive significant unstable medical condition disease study ; Condition , opinion Investigator , could interfere participation study would put patient unacceptable risk ; History noncompliance medical regimen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>